Claudio Zanna

1.9k total citations
49 papers, 1.4k citations indexed

About

Claudio Zanna is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Claudio Zanna has authored 49 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 25 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Claudio Zanna's work include Cell death mechanisms and regulation (12 papers), Cancer Treatment and Pharmacology (12 papers) and Fibroblast Growth Factor Research (11 papers). Claudio Zanna is often cited by papers focused on Cell death mechanisms and regulation (12 papers), Cancer Treatment and Pharmacology (12 papers) and Fibroblast Growth Factor Research (11 papers). Claudio Zanna collaborates with scholars based in Switzerland, Italy and United States. Claudio Zanna's co-authors include Guido Cavaletti, Sante Cundari, Andrea Alberto Lissoni, Augusto Caraceni, Giulia Bianchi, A. Zincone, Marco Piatti, L. Marzorati, G. Bogliun and Barbara Frigeni and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer Research.

In The Last Decade

Claudio Zanna

49 papers receiving 1.3k citations

Peers

Countries citing papers authored by Claudio Zanna

Since Specialization

Citations

This map shows the geographic impact of Claudio Zanna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudio Zanna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudio Zanna more than expected).

Fields of papers citing papers by Claudio Zanna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudio Zanna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudio Zanna. The network helps show where Claudio Zanna may publish in the future.

Co-authorship network of co-authors of Claudio Zanna

This figure shows the co-authorship network connecting the top 25 collaborators of Claudio Zanna. A scholar is included among the top collaborators of Claudio Zanna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudio Zanna. Claudio Zanna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer 2021 ·Clinical and Translational Science ·Carlos Gomez‐Roca, Caroline Even, Christophe Le Tourneau, Neus Basté, Jean‐Pierre Delord, Jérôme Sarini, S. Vergèz, Stéphane Temam, Caroline Hoffmann, Philippe Rochaix, Édith Borcoman, Bruno Gavillet, Elisabeth Rouits, Annick Ménétrey, Franck Brichory, Daniela Purcea, Grégoire Vuagniaux, Claudio Zanna	17
2	Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck 2020 ·Clinical Cancer Research ·Christophe Le Tourneau, Yungan Tao, Carlos Gomez‐Roca, Valérie Cristina, Édith Borcoman, Éric Deutsch, Rastislav Bahleda, Valentin Calugaru, A. Modesto, Elisabeth Rouits, Kathrin Gollmer, Grégoire Vuagniaux, (unknown), Claudio Zanna, Sergio Szyldergemajn, Jean‐Pierre Delord, Jean Bourhis	22
3	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations 2019 ·Clinical Cancer Research ·Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric‐Bernstam, Josep Tabernero, Filip Jankú, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, (unknown), Valerie Nicolas‐Métral, (unknown), Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, José Baselga	102
4	Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results 2019 ·Annals of Oncology ·Ignacio Matos, Lipika Goyal, James M. Cleary, Martin H. Voss, Do‐Youn Oh, (unknown), Cedric Chuan Young Ng, Gopa Iyer, (unknown), Youyou Hu, Anne Vaslin Chessex, (unknown), Valérie Nicolas, (unknown), Claudio Zanna, Keith T. Flaherty, Josep Tabernero, David M. Hyman	4
5	Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model 2018 ·Contrast Media & Molecular Imaging ·Pierre‐Simon Bellaye, Alexandra Oudot, Jean‐Marc Vrigneaud, Olivier Raguin, Francis Bichat, Anne Vaslin, Hélène Maby–El Hajjami, Claudio Zanna, Grégoire Vuagniaux, P. Fumoleau, Franck Denat, François Brunotte, Bertrand Collin	2
6	The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma 2015 ·Radiotherapy and Oncology ·Oscar Matzinger, David Viertl, Pelagia Tsoutsou, (unknown), (unknown), Claudio Zanna, Norbert Wiedemann, Marie‐Catherine Vozenin, Grégoire Vuagniaux, Jean Bourhis	45
7	Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia—Results of a Phase I Dose-Escalation Study 2015 ·Clinical Lymphoma Myeloma & Leukemia ·John F. DiPersio, Harry P. Erba, Richard A. Larson, Selina M. Luger, Martin S. Tallman, (unknown), Grégoire Vuagniaux, Elisabeth Rouits, John M. Sorensen, Claudio Zanna	36
8	Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study 2015 ·Cancer Chemotherapy and Pharmacology ·Herbert I. Hurwitz, David C. Smith, Henry C. Pitot, (unknown), Rashmi Chugh, Elisabeth Rouits, Joseph Rubin, John H. Strickler, Grégoire Vuagniaux, John M. Sorensen, Claudio Zanna	61
9	Abstract 2700: The IAP inhibitor Debio 1143 reverses carboplatin resistance in ovarian cancer cells by inducing both apoptosis and necroptosis 2015 ·Cancer Research ·Benoît Thibault, (unknown), (unknown), M. Barbier, Claudio Zanna, Grégoire Vuagniaux, Jean‐Pierre Delord, Bettina Couderc	1
10	Chemotherapy‐induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale 2011 ·Journal of the Peripheral Nervous System ·Barbara Frigeni, (unknown), Francesca Lanzani, Paola Alberti, (unknown), Claudio Zanna, (unknown), (unknown), Guido Cavaletti	58
11	The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale 2007 ·Journal of the Peripheral Nervous System ·Guido Cavaletti, Barbara Frigeni, Francesca Lanzani, (unknown), (unknown), Chiara Briani, Gabriella Zara, R. Plasmati, Francesca Pastorelli, Augusto Caraceni, Andrea Pace, (unknown), Andrea Alberto Lissoni, Nicoletta Colombo, Giulia Bianchi, Claudio Zanna, (unknown)	194
12	Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors 2006 ·Annals of Oncology ·Cristiana Sessa, Sara Cresta, Thomas Cerny, José Baselga, (unknown), Alessandra Malossi, Dagmar Hess, José Trigo, Massimo Zucchetti, Maurizio D’Incalci, A. Zaniboni, Giuseppe Capri, (unknown), Paolo Carminati, Claudio Zanna, Silvia Marsoni, Luca Gianni	21
13	IART®: Intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation 2006 ·The Breast ·Giovanni Paganelli, Mahila Ferrari, Marta Cremonesi, Concetta De Cicco, Viviana Galimberti, Alberto Luini, Paolo Veronesi, M. Fiorenza, Paolo Carminati, Claudio Zanna, Roberto Orecchia, Umberto Veronesi	20
14	Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. 2005 ·PubMed ·Orlando Ghirardi, Pietro Giudice, Claudio Pisano, Mario Vertechy, (unknown), Loredana Vesci, Sante Cundari, Mariarosaria Miloso, Laura Rigamonti, Gabriella Nicolini, Claudio Zanna, Paolo Carminati	68
15	Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 2004 ·Annals of Oncology ·Guido Cavaletti, G. Bogliun, L. Marzorati, A. Zincone, Marco Piatti, Nicoletta Colombo, D. Franchi, (unknown), Andrea Alberto Lissoni, Alessandro Buda, (unknown), Sante Cundari, Claudio Zanna	90
16	A phase II study of the novel oral camptothecin ST1481 in pretreated metastatic colorectal cancer (CRC) 2004 ·Journal of Clinical Oncology ·C. Boni, Teresa Gamucci, Andrea Bonetti, Giancarlo Bisagni, (unknown), Claudio Zanna, Silvia Marsoni, C. Sessa	4
17	Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity 2002 ·European Journal of Cancer ·Guido Cavaletti, Claudio Zanna	71
18	ANTIHYPERTENSIVE AND METABOLIC EFFECTS OF KETANSERIN IN PATIENTS WITH HYPERTENSION AND IMPAIRED GLUCOSE TOLERANCE : A DOUBLE-BLIND RANDOMIZED, PLACEBO -CONTROLLED, CROSSOVER STUDY 1991 ·Current Therapeutic Research ·Paolo Dessı̀-Fulgheri, Claudio Zanna, (unknown), (unknown), Massimo Paci, Enrique Espinosa, A Rappelli	1
19	The antihypertensive effect of ketanserin versus captopril determined by harmonic fitting. 1991 ·Current Therapeutic Research ·Giuseppe Germanò, (unknown), Valerio Pecchioli, (unknown), (unknown), (unknown), Claudio Zanna, (unknown), Annalisa Santucci	1
20	Comparison of ketanserin and enalapril in the treatment of mild-to-moderate essential hypertension 1990 ·Cardiovascular Drugs and Therapy ·Lorenzo Malatino, Benedetta Stancanelli, Giuseppe Greco, (unknown), (unknown), Claudio Zanna, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact